The company ended the third quarter of 2025 with $715 million in cash, a war chest deemed sufficient to fund both ongoing VANQUISH trials to completion. Research and development expenses jumped to $90 ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading into the new year. Let's consider three that are among my favorites to buy: ...

The FDA has recalled thousands of Ziac blood pressure tablets after traces of a cholesterol drug were found during testing, ...

The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...

And that's why Amazon is a top tech stock to buy and hold for 2026 and beyond. The Motley Fool Stock Advisor analyst team ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...